Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study
Enveric Biosciences Reports Favorable Brain Activity Data for Lead Psychiatric Drug Candidate
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Enveric Biosciences Receives U.S. Patent Office Notice Of Allowance For An Application Covering Novel Compounds Within Its EVM401 Series Of Drug Candidates
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Enveric Biosciences Announces New Preclinical Data That Further Supports The Non-Hallucinogenic Profile Of EB-003; GloSensor Assay Findings Align With Previously Reported BRET Data
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Initiates Investigational New Drug-enabling Genotoxicity Studies Of EB-003
Enveric Biosciences Q1 EPS $(1.08) Up From $(14.64) YoY
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.